Jabil (JBL) Faces FDA Warning, Is The Stock Still Undervalued?

What the FDA warning letter to Jabil means for investors

The FDA issued a detailed warning letter to Jabil (JBL) over significant Current Good Manufacturing Practice violations at its Pharmaceutics International sterile drug facility, raising questions about operational controls and quality oversight.

For you as a shareholder or potential investor, the focus now is on understanding how these regulatory findings relate to Jabil's broader business, its regulated industries segment, and any potential follow up actions the company may need to take.

Jabil's share price has eased in recent months, with a 30 day share price return of 6% and a 90 day share price return of almost 20% in the red, even though the year to date share price return is 24.5% and the 5 year total shareholder return is close to 4x.

Scan a curated group of stocks in tightly regulated sectors that combine quality controls with financial strength using the list of solid balance sheet and fundamentals (52 results).

Given Jabil's recent pullback alongside strong multi year returns, investors now need to judge whether the FDA issues point to a deeper business reset or if sentiment has simply swung too far. The valuation section tests that tension.

Most Popular Narrative: 32.2% Undervalued

Based on the most widely followed narrative, Jabil's fair value sits at $441.44 compared to the last close of $299.39, which suggests a large valuation gap that investors now need to weigh against the FDA warning backdrop.

The analysts have a consensus price target of $441.44 for Jabil based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $482.0, and the most bearish reporting a price target of just $365.0.

Read the complete narrative.

Want to understand why this narrative points to such a different price than the market? The core assumptions stack revenue growth, margin expansion, and a future earnings multiple into a single valuation story. Curious which of those levers does most of the heavy lifting in that $441.44 figure and how sensitive the outcome is if they shift even slightly?

Result: Fair Value of $441.44 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh clear pressure points for Jabil, including revenue declines in Regulated Industries, Connected Living, and Digital Commerce, which could challenge the bullish narrative.

Find out about the key risks to this Jabil narrative.

Another view on Jabil's valuation

The earlier narrative leans on analyst targets and earnings forecasts to argue Jabil is undervalued at $299.39. A separate look using the SWS DCF model also flags the stock as undervalued, with an estimated future cash flow value of about $510.53. Which story do you trust more: the earnings multiple or the cash flow math?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed signals around Jabil's valuation and regulatory risk can feel confusing. Act while the details are fresh and weigh the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Jabil?

If you want a broader view than Jabil alone, now is a good time to scan other stocks with strong fundamentals before the next set of headlines hits.

• Spot potential turnaround candidates early by reviewing the 21 elite penny stocks with strong financials that already pair higher quality financials with tighter discipline on balance sheets.
• Target quality at a reasonable price by checking the 54 high quality undervalued stocks that combine solid fundamentals with valuations that still look reasonable on key metrics.
• Strengthen the defensive side of your portfolio by focusing on the 11 dividend fortresses that aim to balance income potential with underlying business resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com